On the morning of September 7, a delegation from the Hong Kong Hospital Authority and the Hong Kong Island East Cluster visited Shenzhen Cell Valley for an exchange visit. The delegation was led by Dr. So Kit Ying, Cluster Chief Executive of the Hong Kong Island East Cluster, and included Dr. Cheng Yuk-wah, Department Manager of Clinical Pathology; Ms. Lee Shuk-nei, General Manager of Administrative Affairs; Mr. Tai Chi-wah, Medical Engineer; and Dr. Sung Chung, Department Head of Clinical Oncology at Pamela Youde Nethersole Eastern Hospital.They were warmly received by Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley; Professor Wang Jianxun, Chief Scientist; Mr. Zhou Zhaobin from Cell Valley (Hong Kong) Holdings, the company's Hong Kong subsidiary; Wei Zheng, Assistant to the Chairman; and Sun Rui, Head of the Marketing Department.

Led by Chairman Professor Shi Yuanyuan, the visiting delegation toured Shenzhen Cell Valley's Digital Intelligence Exhibition Hall, GMP R&D and Production Laboratories, and Quality Management Laboratory. During the visit, they gained firsthand insights into the latest research achievements in cell therapy and the laboratory layout at Shenzhen Cell Valley.

At the subsequent symposium, Chairman Professor Shi Yuanyuan provided a comprehensive overview of Shenzhen Cell Valley's strategic planning, core technologies, and R&D team. During the meeting, Chairman Shi emphasized that, in accordance with its strategic development plan, Shenzhen Cell Valley has established a subsidiary in Hong Kong—Cell Valley (Hong Kong) Holdings. This milestone marks significant progress in the company's strategic deployment for the year.Furthermore, he noted that the Shenzhen Cell Valley R&D team has recently collaborated with medical teams from local public Grade-A tertiary hospitals to publish a clinical case study in a prestigious international journal. The study details the first successful clinical cure of advanced multiple myeloma using CAR-T cell therapy targeting BCMA, prepared via retroviral vector technology. This case demonstrates that the clinical-grade cell products manufactured by Shenzhen Cell Valley possess high yield, low cost, and efficient transfection and in vivo expansion capabilities. It is precisely these significant advantages that have earned high recognition from the medical community.

Dr. So Kit Ying expressed high recognition of Shenzhen Cell Valley's strategic development plan, core technologies, and clinical application cases. She introduced that the Hong Kong Island East Cluster is managed by the Hospital Authority (HA) of Hong Kong. The HA implements a unified administrative and service management system, establishes standardized clinical protocols aligned with international standards, and oversees the cluster.The cluster serves the Eastern District, Wan Chai, and the Outlying Islands, covering a population of approximately 800,000, which accounts for about 12% of Hong Kong's total population. Among its facilities, the Pamela Youde Nethersole Eastern Hospital serves as a key regional accident and emergency hospital within the cluster, primarily responsible for providing comprehensive specialist services.Dr. So pointed out that given the trend of an aging population and the continuous growth in the number of patients with chronic diseases, the healthcare sector is facing unprecedented challenges. She expressed her hope that through in-depth collaboration with Shenzhen Cell Valley on research projects and clinical applications, the Hong Kong Island East Cluster can introduce more advanced cell therapy technologies, thereby providing patients with more precise and effective treatment solutions.

At the conclusion of the symposium, both parties reached a consensus to leverage the resource-sharing platform between Shenzhen and Hong Kong. They committed to working together to advance the development of cell therapy in both regions, ultimately aiming to provide higher-quality services to residents of Shenzhen and Hong Kong.